The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with Histocell's proprietary technology.
Co-development agreement with:
Innovation
HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.
Additionally, cells show increased survival rates following implant due to an enhanced resistance against the cytotoxic environment in the injury site.
Development stage
Clinical Phase I/II ongoing.
Phase I completed: 8 patients with acute traumatic spinal cord injury included in 2 sequential cohorts.
Phase IIa ongoing: Randomised, controlled, double-blind. 40 patients with acute traumatic spinal cord injury divided into two groups (control and treated).